建發國際集團(01908.HK)附屬斥7.2億人幣成立合營
建發國際集團(01908.HK)公布,間接全資附屬廈門兆澄垚、廈門國際信託、福建兆豐、建發嘉潤及廈門利源訂立合作協議,廈門兆澄垚與廈門國際信託同意成立合營企業,由廈門兆澄垚與廈門國際信託分別擁有80%及20%股權,分別出資7.2億元人民幣(下同)及1.8億元。建發嘉潤及廈門利源將向合營企業出售福建兆豐的100%股權,代價為2,002.4萬元,福建兆豐的註冊資本將由2,000萬元增加至9億元。
完成合作協議項下擬進行交易後,廈門兆澄垚將直接持有合營企業的80%股權,而合營企業則持有福建兆豐的100%股權。合營企業及福建兆豐將成公司附屬,其財務業績將於公司綜合財務報表內綜合入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.